OncoMatch/Clinical Trials/NCT07153068
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Is NCT07153068 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies supCD7 CART cells for t lymphoblastic leukemia/lymphoma.
Treatment: supCD7 CART cells — The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase Ⅰ+Ⅱ clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL/LBL cohort. Each cohort was planned to enroll 4-12 patients. SupCD7 CART cells will be administered intravenously to explore the MTD of each cohort using a 3+3 dose escalation and rapid titration design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Biomarker criteria
Required: CD7 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic chemotherapy
Exception: except for pretreatment
Systemic chemotherapy (except for pretreatment) within 1 week
Cannot have received: monoclonal antibody
For those who have received monoclonal antibody therapy, the last time of monoclonal antibody infusion is less than 5 half-lives or 4 weeks (whichever is shorter) at screening
Cannot have received: donor lymphocyte infusion
Received donor lymphocyte infusion (DLI) within 6 weeks
Lab requirements
Kidney function
creatine clearance >60ml/min (cockcroft and gault formula)
Liver function
serum total bilirubin ≤3 times the upper limit of normal, serum alt and ast ≤5 times the upper limit of normal range for patients without liver invasion
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify